Denosumab as a Treatment Alternative for Central Giant Cell Granuloma: A Long-Term Retrospective Cohort Study.

Publication

Denosumab as a Treatment Alternative for Central Giant Cell Granuloma: A Long-Term Retrospective Cohort Study.

Journal Paper/Review - Sep 21, 2017

Bredell Marius, Rordorf Tamara, Kroiss Sabine, Rücker Martin, Zweifel Daniel Fritz, Rostetter Claudio

Citation

Bredell M, Rordorf T, Kroiss S, Rücker M, Zweifel D, Rostetter C. Denosumab as a Treatment Alternative for Central Giant Cell Granuloma: A Long-Term Retrospective Cohort Study. J Oral Maxillofac Surg 2017; 76:775-784.

Type

Journal Paper/Review (English)

Journal

J Oral Maxillofac Surg 2017; 76

Publication Date

Sep 21, 2017

Issn Electronic

1531-5053

Pages

775-784

Brief description/objective

Giant cell granuloma (GCG) of the jaw is a rare disease with high morbidity. Various treatment options have been discussed in the past. Since 2010, a pharmaceutical therapy with denosumab seems to have been successful for giant cell tumors of the femur. The authors hypothesized the equally successful use of denosumab for GCGs of the jaws.